crohn's disease

Oxazolone has been used as a haptenizing agent, which can induce an inflammatory reaction in adult zebrafish intestinal tissues and this can be used as a model for gene expression studies of the two forms of inflammatory bowel disease like Crohn's disease

5-Acetylsalicylic acid (5-acetyl-2-hydroxybenzoic acid) has anti-inflammatory effects and can be used to treat inflammatory bowel disease, including ulcerative colitis, inflamed anus or rectum, and to maintain remission in Crohn's disease.

Etiprednol dicloacetate (BNP-166) is a corticosteroid with anti-inflammatory activity.Etiprednol dicloacetate inhibits the accumulation of eosinophils and can be used in the study of inflammatory airway diseases such as asthma and in the treatment of Crohn's disease.

Infliximab is a humanized antibody against tumor necrosis factor α TNF-α) that is used in the treatment of Crohn's disease and rheumatoid arthritis.

SEW 2871 is an orally available, highly selective S1P1 agonist with an EC50 of 13.8 nM.It reduces the number of lymphocytes in the blood and is used in studies related to diabetes, Alzheimer's disease, liver fibrosis, and inflammation. It activates ERK, Akt and Rac signaling pathways and induces S1P1 internalization and recycling.

Sibofimloc (Antibiotic-202), an antibiotic compound, is used in treating bacterial infections.

Cosyntropin (acetate) stimulates the release of corticosteroids such as cortisol from the adrenal gland.

Ozanimod (RPC-1063) (RPC1063) is a specific oral S1P Receptor 1 modulator. Ozanimod has been used in trials studying the treatment of Crohn's Disease, Ulcerative Colitis, Multiple Sclerosis, and Relapsing Multiple Sclerosis.

Tulisokibart (PRA023) is a humanized IgG1-κ monoclonal antibody targeting TNFSF15 TL1A, with potential applications in researching inflammatory and fibrotic diseases, including Crohn's Disease (CD) [1] [2].

Certolizumab pegol (Certolizumab) is a recombinant, humanized monoclonal antibody fragment modified with polyethylene glycol (PEG), selectively targeting and neutralizing tumor necrosis factor-alpha (TNF-α). This compound is utilized in research for rheumatoid arthritis and Crohn's disease [1] [2].

Filgotinib (maleate) is a selective, orally active JAK1 inhibitor that effectively inhibits the activity of JAK1 (IC50: 10 nM), JAK2 (IC50: 28 nM), JAK3 (IC50: 810 nM) and TYK2 (IC50: 116 nM). maleate) can be used to study rheumatoid arthritis (RA) and Crohn's disease.

Filgotinib hydrochloride hydrate is a potent and selective JAK1 inhibitor under investigation for the treatment of rheumatoid arthritis (RA) and Crohn's disease.

CP-461 (OSI-461) is a pde2a / 5A inhibitor, which may be used in the treatment of renal cell carcinoma, prostate cancer, and Crohn's disease.

Mongersen (GED-0301), a specific and orally active SMAD7 antisense oligonucleotide, enhances TGF-β1 activity, reducing inflammatory signals. It has been shown to alleviate experimental colitis resembling Crohn's disease in mice [1] [2].

Duvakitug, a humanized IgG1-λ2 monoclonal antibody, targets TNFSF15/TL1A and is primarily expressed in CHOK1SV cells with endogenous glutamine synthetase (GS) activity. It has applications in the research of Crohn's Disease (CD) [1] [2].

Eldelumab (BMS-936557) is a humanized anti-IP-10 IgG type 1 monoclonal antibody with inhibitory activity against CXCL10. It has anti-inflammatory properties, selectively binds to CXCL10, and can be used in the study of rheumatoid arthritis, ulcerative colitis, and Crohn's disease.

Onercept, a recombinant soluble form of the human tumor necrosis factor-alpha (TNF-α) p55 receptor, is utilized in the study of Crohn's disease [1].

Brazikumab (AMG 139), a human IgG2 monoclonal antibody, selectively targets the p19 subunit of IL-23 with a dissociation constant (K D) of 0.138 nM, indicating high affinity for human IL-23. It is employed in Crohn's disease research [1].

Ravagalimab (ABBV-323), a CD40 antagonist with an EC50 of 3.7 nM, is utilized in the research of Crohn's disease [1].

Semapimod tetrahydrochloride (CPSI-2364 tetrahydrochloride) is a synthetic ornithine mitogen-activated protein kinase blocker and pro-inflammatory cytokine production inhibitor that interferes with macrophage and microglia function. Sematimod tetrahydrochloride inhibits TLR4 signaling, TNF-α, IL-1β, and IL-6, and is used in the study of Crohn's disease and other inflammatory conditions.

Teduglutide TFA, a dipeptidyl peptidase IV-resistant glucagon-like peptide-2 (GLP-2) analogue, exhibits trophic effects on the gut mucosa and is used in research related to short bowel syndrome (SBS) and Crohn's disease (CD) [1] [2].

Vedolizumab, a humanized monoclonal antibody, targets the α4β7 integrin for treating Crohn's disease and ulcerative colitis.

Glepaglutide (ZP1848), a long-acting glucagon-like peptide-2 (GLP-2) analogue, functions as a potent GLP-2 receptor (GLP-2R) agonist, effectively reducing fecal output and enhancing intestinal absorption while alleviating small intestine inflammation. It holds potential for researching inflammatory bowel disease (IBD) and Crohn's disease [1] [2] [3].

Visilizumab, a humanized IgG2 monoclonal antibody with low Fc receptor binding affinity, targets the CD3 epsilon (CD3ε) subunit. It is utilized in research related to ulcerative colitis and Crohn's disease [1].

Delmitide, a TNF-alpha production inhibitor, is used potentially for the treatment of Crohn's disease and ulcerative colitis.

Natalizumab used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease.